The drug has received a nod from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey.

The UK is regaining its position as a global hub for industry clinical trials, according to the ABPI, but challenges remain in the space.

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory multiple myeloma.

Amgen is investing $1bn to build a second drug substance manufacturing facility in Holly Springs, North Carolina – increasing the company’s total planned investment in the region to more than $1.5bn.

In a victory for people with sickle cell disease, the US government has announced a major step towards improving access to treatment.

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new breakthroughs and more.

As the MHRA begins a new chapter, the ABPI has published a report outlining the importance of regulatory excellence in the UK.

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.

Research supported by AstraZeneca has demonstrated that a single dose of benralizumab significantly reduces treatment failure rates – by four times compared to traditional steroid tablets.

President-elect Donald Trump has picked the final post in his health team, selecting Dr Jay Bhattacharya to be Director of the US National Institutes of Health.

Europe must act urgently to back small and medium-sized enterprises (SMEs) in the biopharmaceutical sector, says the EFPIA.

Pfizer’s anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.

The novel IL-17A and IL-17F inhibitor has been approved the treatment of moderate to severe hidradenitis suppurativa, a chronic and painful skin disease.

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.  

Revisto has raised $4m in seed funding to simplify the pharmaceutical industry’s marketing compliance processes using AI.

Discover how PTC Therapeutics’ treatment for a rare and fatal genetic disorder called aromatic l-amino acid decarboxylase (AADC) deficiency reached approval

Europe’s pharmaceutical research and development sector is in a tight spot as new data reveals that R&D spending isn’t keeping up with global competitors.

Discover how AZ’s capital investment is set to expand its US research and manufacturing capabilities by the end of 2026.

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players, according to GlobalData.

Johnson & Johnson MedTech has received FDA approval for its device for drug-refractory paroxysmal atrial fibrillation.

With Donald Trump securing a second presidential term, what issues should be top of mind for the pharmaceutical sector in the US? 

AstraZeneca’s new weight-loss pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Catch up on all the biggest news to hit the pharmaceutical industry last month, spanning from new acquisitions, approvals, insights on the NHS and more.

Boehringer Ingelheim, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient advocacy groups.

UPM Biochemicals, Selenis and Bormioli Pharma have introduced the pharmaceutical industry’s first bottle made with wood-based PET.

Take a look at the latest examples of how pharma and its partners are working together to develop technology to solve key challenges.

The Association of the British Pharmaceutical Industry has expressed support for the first Labour budget in 14 years.

Pfizer and Merck’s pneumococcal vaccines have been recommended for adults aged 50 and over in the US, potentially opening up a new market.

The acquisition strengthens Merck’s oncology portfolio as the company looks to off the expiration of the patent for pembrolizumab.

Healthcare professionals’ trust in the pharmaceutical industry has risen since 2020, with many doctors and nurses now expressing high trust.

Discover how this partnership could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations in the Americas.

The British government is set to explore whether Eli Lilly’s weight-loss drug could play a pivotal role in getting people back to work.

Lundbeck will acquire Longboard Pharmaceuticals, aiming to strengthen its portfolio with its potential blockbuster epilepsy treatment.

Eli Lilly and Company appoints their first Chief AI Officer in Thomas J. Fuchs, to spearhead the strategic direction and leadership of AI.

Catch up on all the biggest news to hit the pharmaceutical industry this September, including new appointments, mergers and acquisitions, approvals and more.

For the pharmaceutical industry, this situation highlights ways to step in as partners in healthcare innovation and support the NHS during a turbulent time.

American researchers Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize in Physiology or Medicine for their pioneering discovery of microRNA.

A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention efforts

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth $850M.